This board has been closed to posting. An alternative board can be found here:
Home > Boards > US OTC > Medical - Drugs >

Entest Group Inc.

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 7/26/2018 10:15:57 AM - Followers: 405 - Board type: Free - Posts Today: 0

                         Regen BioPharma Issues End of Fiscal Year Shareholder Letter

PR Newswire PR NewswireSeptember 19, 2017

SAN DIEGO, September 19, 2017 /PRNewswire/ --

Regen BioPharma Inc. (RGBP) and (RGBPP) President Dr. Harry Lander issued the following fiscal year end shareholder letter:

As the end of Regen's fiscal year 2017 approaches on September 30th, I would like to summarize our progress during the past twelve months and look to the future.

The Marketplace:

Our decision to focus on small molecules to activate and inhibit our primary target of interest, NR2F6, seems prescient. The M&A market indicates that the autoimmunity and immuno-oncology fields are even hotter at the end of the year than they were at the beginning. Although there have been many transactions over the past twelve months, two very recent deals further support this assertion: the $2.3 billion acquisition of IFM Therapeutics, Inc. by Bristol Myers Squibb (which I commented on previously (, and the $11.9 billion acquisition of Kite Pharmaceuticals by Gilead (

A Look Back at our Success:

The scientific program focusing on identifying and optimizing small molecule compounds that activate or inhibit NR2F6 and directly inhibit or activate the immune system, respectively, is proceeding well. To our great excitement, we believe we are only three or four months away from having an optimized activator in hand, which we can then test in several animal models of autoimmunity. Similarly, we also expect to have an optimized inhibitor a few months afterward (in calendar Q1 of 2018), which we can then test it in several animal models of cancer.

Plans for the Immediate Future:

We continue to have discussions with multiple big pharma companies. To create the most value for our shareholders, we have elected to continue to develop the NR2F6 program in-house prior to entering into any potential partnerships. The more mature the products, the greater their valuation in the marketplace.

We are now in the process of identifying the major indications on which we will focus our efficacy studies. Obviously, the market size of an indication is important, but equally or even more important is the likelihood of success. Therefore, although we already have a preferred list of indications, we will test these compounds for efficacy in many models of autoimmunity and cancer. Our goal in 2018 is to develop both an activator and inhibitor of NR2F6 that is effective and not toxic in animal models. At that point, we will begin experiments and process manufacturing, which will enable us to apply for testing these compounds in humans.

The drug development process is slow and steady. However, we have had no scientific setbacks, and the small molecule drugs that we are developing are performing exactly as we had hoped they would. This is not usually the case in science and we remain laser-focused on achieving the scientific goals we have set out to achieve. Thus far, we have met each and every scientific target, and we believe that our planned scientific efforts in 2018 will greatly increase the likelihood of striking strategic partnerships with one or more large pharmaceutical companies in the near future.

With warm regards,

Harry Lander

President and Chief Scientific Officer  

Brian Devine, Chairman
Business Advisory Board

Brian is the former Chairman, CEO, and President of PETCO, where he oversaw the company’s expansion from $80 million to approximately $5 billion in sales. He became Chairman Emeritus at Petco Holdings, Inc. in 2016. Prior to that, he held leadership roles at Toys R Us, including Senior Vice President, Director of Stores for the U.S and Canada. Brian served as a Director at National Retail Federation Inc., Retail Industry Leaders Association, Students in Free Enterprise, Georgetown University Board of Regents, Georgetown University College Board of Advisors, San Diego International Sports Council, and the San Diego Padres.  He also served as Director, Chairman of Real Estate Committee, Member of Executive Committee and Member of Nominating Committee at Wild Oats Market prior to it being sold to Whole Foods. He currently is on the Board of Directors of the Ron Fowler School of Business at San Diego State University, the San Diego Sports Alliance, the San Diego Hall of Champions, and on private company boards.



?Zander Therapeutics is a biotechnology company focused on veterinary therapies that enlist the animals’ own immune system.  Zander’s main areas of interest include: autoimmune disorders such as arthritis, immunotherapies for cancer treatment in canines and bone marrow suppression therapy for animals treated with chemotherapy and radiation therapy.
??Learn more about bone marrow and aplastic anemia therapy as well as small molecule targeting cancer stem cell genes.


Products in Development for Veterinary Use

  • ZT 110 is an NR2F6 inhibitor feline leukemia
    ZT 240 is an NR2F6 inhibitor for canine cancer
    ?ZT 396 is an NR2F6 stimulator for exercise induced pulmonary hemorrhage (equine)
    ZT 430 is an NR2F6 stimulator for arthritis and autoimmunity (feline & canine)


Small Molecule Therapies Targeting Cancer Stem Cell Genes in Animals?

Small Molecule targeting of the cancer stem cell is the process of “coaxing” the cancer stem cell to turn into a normal cell. Regen BioPharma (licensor) has identified and filed patents on a novel gene controlling the process of cancer stem cell differentiation. Additionally, Zander Therapeutics has filed its own patent applications regarding therapies for animals.?
  • Objective is to identify small molecules that can induce differentiation of cancer stem cells 
    High through-put screening identified 7 “hit” compounds 
    Currently in pre-clinical development 
    Additional indications include solid tumors and acute leukemia


Small Molecule Therapies Targeting Autoimmune Diseases Genes in Animals

The Company believes that autoimmune diseases such as arthritis can be controlled and their impact reversed by activating a gene in animals that is believed to modulate this process.  This set of therapies is based upon intellectual property licensed by Zander Therapeutics from Regen BioPharma.  Zander Therapeutics is pursuing its own intellectual property that will build on currently licensed technology.
  • Objective is to identify small molecules that activate NR2F6 check point that appears to control autoimmune diseases

    Currently in pre-clinical development 


Bone Marrow and Aplastic Anemia Therapy

A personalized cellular therapeutic product designed to stimulate blood production in veterinary patients whose bone marrow is not properly functioning.
  • Fat stem cell-based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemotherapy or chronic conditions
    Uses animal’s own fat as a source of endothelial cells to heal damaged bone marrow 
    Toxicity studies have been successfully completed by Regen BioPharma Inc., the licensor of this technology to Zander Therapeutics
    Aims to provide “natural” replacement to synthetic cytokines
For cats and dogs, Zander will target:
  • Arthritis
    Autoimmune Disorders
    Feline Leukemia

For horses, Zander will target:
  • Exercise Induced Pulmonary Hemorrhage (EIPH)

United States Food and Drug Administration (FDA) Investigational New Drug Application (IND #15376, status cleared for use in humans by Regen BioPharma Inc. -- licensor to Zander Therapeutics Inc.)






Zander Therapeutics, Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942

Telephone: (619) 702-1404
Fax: (619) 330-2328



David R. Koos, PhD, DBA
Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 32 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.

?Harry Lander, PhD, MBA
President and Chief Scientific Officer

Harry Lander has over 20 years of professional scientific, business and financial management experience related to biomedical research.  He has a deep knowledge of operations and research administration.  Dr. Lander has a team-oriented management style founded on outstanding communication and interpersonal skills.  Highly effective at strategic planning, problem solving and operational excellence.  Dr. Lander has extensive relationships with large and small biotechnology / pharmacology companies and entities that Regen BioPharma expects to leverage for company growth.

Formerly he has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University), along with serving as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University).

?Todd S. Caven
Chief Financial Officer 

Todd S. Caven is an accomplished executive with 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States.

In 2003, Mr. Caven founded Rock Ridge Enterprises, a Minnesota-based boutique Private Equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Prior to founding Rock Ridge Enterprises, he served as the CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately held firm in the Staffing and Recruiting industry. Prior to Atterro, Todd held senior-level finance and marketing positions at Nordic Track and the Carlson Companies, both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum).

Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

Thomas Donnelly, DVM
Senior Veterinary Advisor

Tom is a board-certified specialist in the field of laboratory animal medicine. He is also Adjunct Associate Professor at Tufts University Cummings School of Veterinary Medicine and Professor (teaching & research) at Ecole Nationale Veterinaire d’Alfort. He provides regulatory guidance, research advice, medical attention and welfare supervision to researchers using animals in scientific investigation and testing. Tom is a board-certified specialist in the field of exotic mammals, and sees primary care and referred patients. His work links the understanding of animal diseases and their complexities with the development of novel therapies for humans and animals.

Linda L. Black, DVM, PhD 
Senior Veterinary Advisor

Linda is a leading researcher, published author and currently COO and Vice President of Clinical Science for Medicus Biosciences, a biotech company focused on drug delivery for ophthalmology, advanced wound healing, osteoarthritis, and regenerative medicine applications for pets and people. She has extensive experience in veterinary stem cell research and commercialization. She holds a PhD in Molecular and Cell Biology from The Wistar Institute at University of Pennsylvania School of Medicine, a DVM from University of Wisconsin School of Veterinary Medicine and attended undergraduate training at the University of California at Davis. She completed her post doctoral fellowship at GlaxoSmithKline.

?Thomas Ichim, PhD
Senior Research Consultant

Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. He spent over seven years as President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. 

?Debbie Dorsee
Director of Business Development

The Dorsee Company, founded by Debbie Dorsee, is a leader in public relations for businesses and individuals. With an integrated focus on community relations, marketing, fundraising/capital raising, and business development, The Dorsee Company offers a unique promotional approach that opens doors, forges partnerships, and drives results.
Debbie Dorsee, a San Diego native, founded The Dorsee Company in 2003. Drawing from her life’s fabric of political campaigns, social events and promotional fundraising, she uses her behind-the-scenes knowledge and community contacts to promote public awareness and drive business results. Debbie was the recipient of the San Diego North Chamber of Commerce’s Volunteer of the Year honor and was named one of San Diego Metropolitan Magazine’s Metro Movers to Watch

Jonathan Baell, PhD
Scientific Advisory Board

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines for treating diseases with an unmet medical need. A proven record of undertaking original research with a total of 120 publications and patents. He is published in top-ranked journals in the field (e.g. 12 in Journal of Medicinal Chemistry, Nature Chemical Biology,Nature).  He has 40 granted patents listed in

He has won a national award for my discovery of a new class of potential multiple sclerosis therapeutics. Additionally he has achieved successful outcomes in a diverse array of drug discovery arenas, from rational design of peptidomimetics to heterocyclic drug discovery.

For the period 2012-16, Dr. Baell is Chief InvestIgator on competitive grants that currently are totalling $4.73M. In addition, he has been awarded a prestigious NHMRC Senior Research Fellowship for the period 2012-2016. In 2011 and elected as the Australian representative to the Board of Directors for the Inaugural International Chemical Biology Society and appointed Chair of Membership.


 Recent News!  Check out Zander therapeutics website.





PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#38376   Hoping for a good day kid70 07/26/18 10:15:56 AM
#38375   Quiet period right now can't say much at the reaper 06/26/18 12:44:47 PM
#38374   hi parrishilton, you where right about ohmyohmy 04/22/18 11:19:11 AM
#38373   YUP....It also shows up on BARCHARTS. Ihub choctaw 04/11/18 10:48:49 PM
#38372   There does cashclan 03/15/18 08:54:42 AM
#38371   I found it on IHub. salesleader 02/19/18 10:38:41 AM
#38370   There is no ETNI board, iTrader 02/17/18 04:37:21 PM
#38369   Ron Rooster has set up a new board salesleader 02/17/18 11:46:03 AM
#38368   you may or may not be right salesleader 02/16/18 09:51:00 AM
#38367   you might be right or wrong ? parrishilton 02/15/18 05:15:45 PM
#38366   hard to say someone must know parrishilton 02/15/18 05:15:06 PM
#38365   why does this happen ? parrishilton 02/15/18 05:14:23 PM
#38364   sure looks great new name parrishilton 02/15/18 05:13:46 PM
#38363   Mods - please update the correct ticker. Kbro13 02/14/18 12:38:04 PM
#38362   ETNI is the new ticker. JokersWild12 02/14/18 08:24:03 AM
#38361   Shows as encounter technologies.... gotinearly 02/14/18 07:56:43 AM
#38360   ENTB symbol changed to ENTI effective February 14, 2018 TenKay 02/13/18 05:36:47 PM
#38359   SORRY.CORRECTION.SHOULD BE ETNI ronrooster 02/13/18 03:48:02 PM
#38358   NEW SYMBOL STARTING FEB 14.ENTI ronrooster 02/13/18 03:36:51 PM
#38357   Could u post link.thanks. ronrooster 02/09/18 12:04:54 AM
#38356   The Entest website is pretty much the Zander jeffshir 02/08/18 04:23:29 PM
#38355   You may be onto something.My thought is that ronrooster 02/05/18 02:21:56 PM
#38354   Ron, perhaps veterinary parasitology gets added to the JokersWild12 02/05/18 02:12:29 PM
#38353   I was just doing a little venting , salesleader 02/02/18 12:25:15 PM
#38352   It’s coming, of u check Edgar, approvals r jeffshir 02/02/18 12:03:07 PM
#38351   LOL , I know down 54% and been salesleader 02/02/18 11:36:55 AM
#38350   Patience, grasshopper jeffshir 02/02/18 11:26:19 AM
#38349   Beginning to wonder if it's going to happen salesleader 02/02/18 11:18:40 AM
#38348   Probably around 144,000 ZANDER shares.if they list at ronrooster 02/01/18 12:58:10 PM
#38347   Somebody will be getting a lot of Zander shares jeffshir 02/01/18 12:17:07 PM
#38346   hmmm salesleader 02/01/18 10:02:21 AM
#38345 gotinearly 02/01/18 09:04:08 AM
#38344   Life secience journeys founded 10/17/17. Wonder how much ctvette2003 02/01/18 06:36:16 AM
#38343   just out..13g statement of ownership.Seems funny that someone ronrooster 01/31/18 06:22:22 PM
#38342   Just for fun..what thoughts as to Entest Group's ronrooster 01/28/18 09:04:35 PM
#38341   $ENTB-Entest Bio Medical changed it's name to Entest the reaper 01/24/18 10:50:43 AM
#38340   Some progress..S-1A out today. Hopefully we get the ronrooster 01/16/18 10:53:04 AM
#38339   Hope it works out for ronrooster 01/14/18 06:39:25 PM
#38338   Ron thanks for the info, after the RS ctvette2003 01/14/18 06:35:50 PM
#38337   It appears you have held ENTB stocks since ronrooster 01/14/18 04:48:46 PM
#38336   LOL Joker, are you really expecting a reasonable ctvette2003 01/11/18 12:09:13 PM
#38335   I am sure we will get more communication ronrooster 01/11/18 11:47:10 AM
#38334   Very interesting indeed.The new name would enable Entest ronrooster 01/11/18 11:42:10 AM
#38333   Entest Biomedical to Entest Group...Why the name change? JokersWild12 01/11/18 11:41:35 AM
#38332   Interesting. "Effective February 12, 2018 the name of the Kbro13 01/11/18 10:29:40 AM
#38331   Current Report Filing (8-k) ronrooster 01/11/18 09:37:30 AM
#38330   Wonder home many companies Koos owns these days? ctvette2003 01/10/18 03:45:18 PM
#38329   This will come in handy in the near jeffshir 01/10/18 03:35:19 PM
#38328   Happy New Year's fellow longs. It's been awfully JokersWild12 01/10/18 02:18:49 PM
#38327   Quarterly report out - buying volume. Kbro13 01/10/18 01:56:39 PM